In a similar manner, Wei Jiang and colleagues developed bispecific c-Met/PD-L1 CAR-T cells that demonstrated superior anti-hepatocellular carcinoma activity compared to monospecific c-Met or PD-L1 CAR-T cells [213]. The gene discussed is MET; the disease is hepatocellular carcinoma.